Detecting Activation of Ribosomal Protein S6 Kinase by Complementary DNA and Tissue Microarray Analysis
Open Access
- 2 August 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 92 (15), 1252-1259
- https://doi.org/10.1093/jnci/92.15.1252
Abstract
Background: Studies by comparative genomic hybridization (CGH) have shown that chromosomal region 17q23 is amplified in up to 20% of primary breast cancers. We used microarray analyses to measure the expression levels of genes in this region and to explore their prognostic importance. Methods: A microarray that contained 4209 complementary DNA (cDNA) clones was used to identify genes that are overexpressed in the MCF-7 breast cancer cell line as compared with normal mammary tissue. Fluorescence in situ hybridization was used to analyze the copy number of one overexpressed gene, ribosomal protein S6 kinase (S6K), and to localize it to the 17q23 region. Northern and western blot analyses were used to measure S6K gene and protein expression, and an enzymatic assay was used to measure S6K activity. Tumor tissue microarray analysis was used to study amplification of S6K and the HER-2 oncogene, another 17q-linked gene, and the relationship between amplification and prognosis was analyzed. The Kaplan–Meier method was used for data analysis, and the log-rank test was used for statistical analysis. All P values are two-sided. Results: S6K was amplified and highly overexpressed in MCF-7 cells relative to normal mammary epithelium, and protein expression and enzyme activity were increased. S6K was amplified in 59 (8.8%) of 668 primary breast tumors, and a statistically significant association between amplification and poor prognosis (P = .0021) was observed. Amplification of both S6K and HER-2 implied particularly poor survival (P = .0001). Conclusions: The combination of CGH information with cDNA and tissue microarray analyses can be used to identify amplified and overexpressed genes and to evaluate the clinical implications of such genes and genomic rearrangements. S6K is likely to be one of the genes at 17q23 that is amplified during oncogenesis and may adversely affect the prognosis of patients with this amplification.Keywords
This publication has 24 references indexed in Scilit:
- Positional cloning of ZNF 217 and NABC 1 : Genes amplified at 20q13.2 and overexpressed in breast carcinomaProceedings of the National Academy of Sciences, 1998
- Molecular cytogenetics of primary breast cancer by CGHGenes, Chromosomes and Cancer, 1998
- Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regionsGenes, Chromosomes and Cancer, 1997
- AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian CancerScience, 1997
- A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell linesOncogene, 1997
- Use of a cDNA microarray to analyse gene expression patterns in human cancerNature Genetics, 1996
- The human CAS (cellular apoptosis susceptibility) gene mapping on chromosome 20q13 is amplified in BT474 breast cancer cells and part of aberrant chromosomes in breast and colon cancer cell lines.Genome Research, 1996
- Serial Analysis of Gene ExpressionScience, 1995
- Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissectionNature Genetics, 1994
- Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization.Proceedings of the National Academy of Sciences, 1994